- Proposed acquisition would combine Gameto’s reproductive-health innovation with Ferring’s
longstanding expertise and global presence in reproductive medicine.
- Signed merger agreement marks an important step towards a potential combination.
Saint-Prex, Switzerland – 27 October 2026– Ferring Pharmaceuticals and Gameto today announced
that they have signed an agreement for a global transaction under which Ferring would acquire
Gameto. Completion remains subject to customary and other closing conditions. Until closing, the
companies will continue to operate independently.
The proposed transaction has a deal value of up to $1.3825 billion, subject to development, regulatory
and commercial milestones.
The transaction would bring together Gameto’s reproductive-health innovation and Ferring’s
longstanding expertise and global presence in reproductive medicine. Gameto’s In Vitro Maturation
programme is investigational in the United States and has not been approved by the U.S. Food and
Drug Administration.
“Ferring has been committed to helping people build families for more than 50 years. By combining
Gameto’s scientific innovation with our expertise and global reproductive-medicine platform, we see an
opportunity to advance new approaches in fertility care and reach more patients worldwide,” said
JeanFrédéric Paulsen, Chairman of the Board of Directors and Chief Executive Officer, Ferring
Pharmaceuticals.
“This is a defining moment for Gameto and for our mission to transform reproductive health. By
combining our pioneering cell-engineering platform with Ferring’s deep expertise and global reach in
reproductive medicine, we have an extraordinary opportunity to accelerate innovation, expand access
and bring more modern fertility treatment options to women and families around the world,” said Dr.
Dina Turner, Chief Executive Officer and Co-founder of Gameto.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a privately owned specialty biopharmaceutical group committed to building
families and helping people live better lives. We are leaders in reproductive medicine with a strong
heritage in gastroenterology and urology and are at the forefront of innovation in uro-oncology gene
therapy. Ferring was founded in 1950 and is headquartered in Saint-Prex, Switzerland. The company
has operating subsidiaries in more than 50 countries and markets its medicines in over 100 countries.
Learn more at www.ferring.com, or connect with us on LinkedIn, Instagram and YouTube.
About Gameto
Gameto is a biotechnology company using cell engineering to develop novel treatment solutions for
women’s reproductive health, starting with infertility. The company is working to address unmet needs
across the reproductive journey through advances in fertility, ovarian disease and menopause.
For more information please contact:
Ferring Pharmaceuticals
Lisa Perdomo
Director, Brand Communications
(862) 341-9820
Lisa.Perdomo@ferring.com